StreetAlpha.app
Home › Stocks › IBIO

iBio, Inc. (IBIO)

$0.75
▲ +5.86%
LAST CLOSE · NOV 17

iBio is a clinical stage biotech developing AI designed antibody drugs for obesity and related heart and lung diseases. It last closed at $0.75 on Nov 17, up 5.86% on the day. IBIO reports earnings on Tue, Feb 9, 2027.

AI Auto Pilots
Is IBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.1M
+115.0% vs a year ago
Net income
−$34.9M
−3244.2% margin
EPS (diluted)
−$0.26
Free cash flow
−$27.6M
−2566.3% margin
Valuation
Market cap
$52.7M
70.5M shares
P/E
–
No P/E while losing money
Price to sales
49.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$45.4M
At Sep 30
Shareholder equity
$78.6M
Shares outstanding
70.5M
At Nov 10
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $1.9M$1.9MFY2022FY2023: $0$0FY2023FY2024: $225K$225KFY2024FY2025: $400K$400KFY2025FY2026: $100K$100KFY2026

From IBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 9
2027 · Time not announced
Consensus EPS forecast
-$0.09
$16,670 revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IBIO in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 835.7% upside

Based on 1 analyst who set a price target on IBIO in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.75.

Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.75
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
HC Wainwright & Co.Initiated
Sep 17Buy$7
Raymond JamesInitiated
Jun 8Buy$5
DateFirmActionRatingPrice target
Sep 17HC Wainwright & Co.InitiatedBuy$7
Jun 8Raymond JamesInitiatedBuy$5
Loading…

Technical Analysis

IBIO · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 28% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $0.74, and the nearest resistance the Pivot R1 at $0.77.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$3.8252 week high+409.3%
$1.61200 day average+114.7%
$1.20100 day average+60.0%
$0.9650 day average+28.0%
$0.84Swing high (Nov 11)+12.0%
$0.7720 day average+2.7%
$0.77Pivot R1+2.7%
$0.75Last close
$0.74Pivot−1.3%
$0.73Swing low (Oct 14)−2.7%
$0.71Pivot S1−5.3%
$0.6852 week low−9.3%
Indicators
RSI (14)41.87Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic28.6Middle of its rangeNeutral
ADX (14)24.8Weak trend
Williams %R-58.3Oversold below −80, overbought above −20Neutral
CCI (20)-77.9Oversold below −100, overbought above 100Neutral
Rate of change−7.8%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IBIO

What happened before

See how IBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IBIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

IBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲27 buying vs 17 selling
  • ▲Held by funds +3.9 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5955+7.3%
In funds' top 1000–
Held by funds53.3%49.3%+3.9 pts
New / increased11 / 1615 / 22−27.0%
Reduced / sold out13 / 49 / 12−19.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBIO is in one of them and how their past IBIO trades turned out.

IBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IBIO in an article yet. Here's the latest on the wider market.

About iBio

iBio is a biotechnology company that uses artificial intelligence to design antibody drugs. Its work focuses on obesity and related heart and lung conditions, including pulmonary hypertension linked to heart failure. Its lead candidate, IBIO-600, is in a Phase 1 clinical trial, and other candidates are in earlier preclinical development. No products are approved yet, so its intended customers are patients with these conditions and the clinicians who treat them. The company is based in New York and conducts its research at a laboratory in San Diego.

Headquarters
New York, NY